• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-20a 通过调节启动子活性调控骨肉瘤细胞中 FAS 的表达,可作为治疗靶点抑制肺转移。

miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.

机构信息

Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Immunotherapy Institute, Fujian Medical University, University Town, Fuzhou, China.

出版信息

Mol Cancer Ther. 2018 Jan;17(1):130-139. doi: 10.1158/1535-7163.MCT-17-0042. Epub 2017 Oct 27.

DOI:10.1158/1535-7163.MCT-17-0042
PMID:29079708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5752589/
Abstract

The metastatic potential of osteosarcoma cells is inversely correlated to cell surface FAS expression. Downregulation of FAS allows osteosarcoma cells to escape FAS ligand-mediated apoptosis when they enter a FAS ligand-positive microenvironment such as the lung. We have previously demonstrated that miR-20a, encoded by the miR-17-92 cluster, downregulates FAS expression in osteosarcoma. We further demonstrated an inverse correlation between FAS expression and miR-20a expression. However, the mechanism of regulation by miR-20a was still unclear. The purpose of the current study was to evaluate the mechanism of regulation by miR-20a and test the effect of targeting miR-20a We investigated whether miR-20a's downregulation of was mediated by binding to the 3'-untranslated region (3'-UTR) of mRNA with the consequent induction of mRNA degradation or translational suppression. We identified and mutated two miR-20a binding sites on the mRNA 3'-UTR. Using luciferase reporter assays, we demonstrated that miR-20a did not bind to either the wild-type or mutated 3'-UTR. In contrast, overexpression of miR-20a resulted in downregulation of promoter activity. Similarly, the inhibition of miR-20a increased promoter activity. The critical region identified on the promoter was between -240 bp and -150 bp. Delivery of anti-miR-20a using nanoparticles in mice with established osteosarcoma lung metastases resulted in upregulation of and tumor growth inhibition. Taken together, our data suggest that miR-20a regulates expression through the modulation of the promoter and that targeting miR-20a using anti-miR-20a has therapeutic potential. .

摘要

骨肉瘤细胞的转移潜能与细胞表面 Fas 表达呈负相关。Fas 表达下调使骨肉瘤细胞在进入 Fas 配体阳性微环境(如肺)时能够逃避 Fas 配体介导的细胞凋亡。我们之前已经证明,miR-17-92 簇编码的 miR-20a 下调骨肉瘤细胞中 Fas 的表达。我们进一步证明 Fas 表达与 miR-20a 表达呈负相关。然而,miR-20a 的调控机制仍不清楚。本研究的目的是评估 miR-20a 的调控机制,并测试靶向 miR-20a 的效果。我们研究了 miR-20a 是否通过与 mRNA 的 3'-非翻译区(3'-UTR)结合来下调 ,从而诱导 mRNA 降解或翻译抑制。我们鉴定并突变了 mRNA 3'-UTR 上的两个 miR-20a 结合位点。通过荧光素酶报告基因检测,我们证明 miR-20a 不能与野生型或突变型 3'-UTR 结合。相反,miR-20a 的过表达导致 启动子活性下调。同样,miR-20a 的抑制增加了 启动子活性。在 启动子上鉴定的关键区域位于-240 bp 和-150 bp 之间。在已建立骨肉瘤肺转移的小鼠中,使用纳米颗粒递送抗 miR-20a,导致 上调和肿瘤生长抑制。综上所述,我们的数据表明,miR-20a 通过调节 启动子来调节 的表达,并且使用抗 miR-20a 靶向 miR-20a 具有治疗潜力。

相似文献

1
miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.miR-20a 通过调节启动子活性调控骨肉瘤细胞中 FAS 的表达,可作为治疗靶点抑制肺转移。
Mol Cancer Ther. 2018 Jan;17(1):130-139. doi: 10.1158/1535-7163.MCT-17-0042. Epub 2017 Oct 27.
2
miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.miR-17-92 簇编码的 miR-20a 通过调节 Fas 表达增加骨肉瘤细胞的转移潜能。
Cancer Res. 2012 Feb 15;72(4):908-16. doi: 10.1158/0008-5472.CAN-11-1460. Epub 2011 Dec 20.
3
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.Fas/FasL 信号通路:在转移过程中的作用及其作为治疗骨肉瘤肺转移的靶点。
Adv Exp Med Biol. 2020;1258:177-187. doi: 10.1007/978-3-030-43085-6_12.
4
Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.Fas/FasL 信号通路与肺部微环境在骨肉瘤肺转移中的作用。
Adv Exp Med Biol. 2014;804:203-17. doi: 10.1007/978-3-319-04843-7_11.
5
The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.组蛋白去乙酰化酶抑制剂 MS-275(entinostat)下调 c-FLIP,使骨肉瘤细胞对 FasL 敏感,并诱导骨肉瘤肺转移瘤的消退。
Curr Cancer Drug Targets. 2013 May;13(4):411-22. doi: 10.2174/1568009611313040005.
6
VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.血管内皮生长因子165(VEGF165)对Fas(-)骨肉瘤细胞的转移潜能至关重要,但无法挽救Fas(+)细胞。
J Exp Ther Oncol. 2008;7(2):89-97.
7
miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1.miR-214 通过直接抑制 LZTS1 促进骨肉瘤细胞的增殖和侵袭。
Biochem Biophys Res Commun. 2014 Jun 27;449(2):190-5. doi: 10.1016/j.bbrc.2014.04.140. Epub 2014 May 4.
8
MicroRNA-26b inhibits metastasis of osteosarcoma via targeting CTGF and Smad1.微小RNA-26b通过靶向结缔组织生长因子(CTGF)和Smad1抑制骨肉瘤转移。
Tumour Biol. 2015 Aug;36(8):6201-9. doi: 10.1007/s13277-015-3305-6. Epub 2015 Mar 12.
9
miRNA-20a upregulates TAK1 and increases proliferation in osteosarcoma cells.miRNA-20a 上调 TAK1 并增加骨肉瘤细胞的增殖。
Future Oncol. 2018 Feb;14(5):461-469. doi: 10.2217/fon-2017-0490. Epub 2018 Jan 12.
10
P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.P65 介导的 miR-590 抑制通过靶向野生型 p53 诱导的磷酸酶 1 调节骨肉瘤对阿霉素的化疗耐药性。
J Cell Biochem. 2019 Apr;120(4):5652-5665. doi: 10.1002/jcb.27849. Epub 2018 Nov 1.

引用本文的文献

1
Recent Advances in Cancer Immunotherapy Aided by Regulatory Non-Coding RNA: A Review.受调控非编码RNA辅助的癌症免疫治疗最新进展:综述
Asian Pac J Cancer Prev. 2025 Jun 1;26(6):1915-1930. doi: 10.31557/APJCP.2025.26.6.1915.
2
Delivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma.利用纳米颗粒递送 miRNA 治疗骨肉瘤。
Int J Nanomedicine. 2024 Aug 22;19:8641-8660. doi: 10.2147/IJN.S471900. eCollection 2024.
3
Reprogramming of glucose metabolism: Metabolic alterations in the progression of osteosarcoma.葡萄糖代谢重编程:骨肉瘤进展中的代谢改变。
J Bone Oncol. 2024 Jan 4;44:100521. doi: 10.1016/j.jbo.2024.100521. eCollection 2024 Feb.
4
Dissecting the role of lactate metabolism LncRNAs in the progression and immune microenvironment of osteosarcoma.剖析乳酸代谢长链非编码RNA在骨肉瘤进展和免疫微环境中的作用。
Transl Oncol. 2023 Oct;36:101753. doi: 10.1016/j.tranon.2023.101753. Epub 2023 Aug 6.
5
miR-aculous new avenues for cancer immunotherapy.miR- 开辟癌症免疫治疗的新途径。
Front Immunol. 2022 Sep 28;13:929677. doi: 10.3389/fimmu.2022.929677. eCollection 2022.
6
Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features.促血管生成分子和事件的上调与转移性骨肉瘤细胞中的血管生成转换无关,而是与细胞存活特征有关。
Apoptosis. 2021 Aug;26(7-8):447-459. doi: 10.1007/s10495-021-01677-x. Epub 2021 May 22.
7
The miR-204-5p/FOXC1/GDF7 axis regulates the osteogenic differentiation of human adipose-derived stem cells via the AKT and p38 signalling pathways.miR-204-5p/FOXC1/GDF7 轴通过 AKT 和 p38 信号通路调节人脂肪源性干细胞的成骨分化。
Stem Cell Res Ther. 2021 Jan 18;12(1):64. doi: 10.1186/s13287-020-02117-4.
8
miR‑543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5.miR-543 通过靶向 CYP3A5 在口腔鳞状细胞癌中发挥 novel oncogene 的作用。
Oncol Rep. 2019 Sep;42(3):973-990. doi: 10.3892/or.2019.7230. Epub 2019 Jul 11.
9
MiR-20a, a novel promising biomarker to predict prognosis in human cancer: a meta-analysis.miR-20a,一种有前途的新型人类癌症预后预测生物标志物:一项荟萃分析。
BMC Cancer. 2018 Nov 29;18(1):1189. doi: 10.1186/s12885-018-4907-3.
10
Identification of Novel Target for Osteosarcoma by Network Analysis.网络分析鉴定骨肉瘤的新靶点。
Med Sci Monit. 2018 Aug 25;24:5914-5924. doi: 10.12659/MSM.909973.

本文引用的文献

1
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.新诊断的高级别骨肉瘤术前化疗反应不佳患者中MAPIE与MAP的比较(EURAMOS-1):一项开放标签、国际、随机对照试验
Lancet Oncol. 2016 Oct;17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5. Epub 2016 Aug 25.
2
MicroRNA‑20a promotes the proliferation and cell cycle of human osteosarcoma cells by suppressing early growth response 2 expression.微小RNA-20a通过抑制早期生长反应2的表达促进人骨肉瘤细胞的增殖和细胞周期。
Mol Med Rep. 2015 Oct;12(4):4989-94. doi: 10.3892/mmr.2015.4098. Epub 2015 Jul 20.
3
Oligonucleotide Therapies: The Past and the Present.寡核苷酸疗法:过去与现在。
Hum Gene Ther. 2015 Aug;26(8):475-85. doi: 10.1089/hum.2015.070. Epub 2015 Aug 3.
4
Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.脂质纳米颗粒递送微小RNA-145抑制剂可改善实验性肺动脉高压。
J Control Release. 2015 Jul 28;210:67-75. doi: 10.1016/j.jconrel.2015.05.261. Epub 2015 May 13.
5
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.治疗性反义寡核苷酸抗癌药物:向临床迈进。
Front Chem. 2014 Oct 14;2:87. doi: 10.3389/fchem.2014.00087. eCollection 2014.
6
Non-viral vectors for gene-based therapy.基于基因治疗的非病毒载体。
Nat Rev Genet. 2014 Aug;15(8):541-55. doi: 10.1038/nrg3763. Epub 2014 Jul 15.
7
Therapeutic targeting of microRNAs: current status and future challenges.治疗性靶向 microRNAs:现状与未来挑战。
Nat Rev Drug Discov. 2014 Aug;13(8):622-38. doi: 10.1038/nrd4359. Epub 2014 Jul 11.
8
CD95 is part of a let-7/p53/miR-34 regulatory network.CD95 是 let-7/p53/miR-34 调控网络的一部分。
PLoS One. 2012;7(11):e49636. doi: 10.1371/journal.pone.0049636. Epub 2012 Nov 14.
9
MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.MS-275 通过增加 Fas 在膜脂筏中的定位,使骨肉瘤细胞对 Fas 配体诱导的细胞死亡敏感。
Cell Death Dis. 2012 Aug 9;3(8):e369. doi: 10.1038/cddis.2012.101.
10
Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis.miRNAs 在肺癌中的作用:miRNA 特征与癌症预后。
Cancer J. 2012 May-Jun;18(3):268-74. doi: 10.1097/PPO.0b013e318258b743.